How to buy PureTech Health shares | 361.5p

Own PureTech Health shares in just a few minutes. Share price changes are updated daily.

Fact checked

PureTech Health plc (PRTC) is a leading biotechnology business based in the UK. It opened the day at 361p after a previous close of 363p. During the day the price has varied from a low of 353p to a high of 370p. The latest price was 361.5p (25 minute delay). PureTech Health is listed on the London Stock Exchange (LSE) and employs 300 staff. All prices are listed in pence sterling.

How to buy shares in PureTech Health

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: PRTC in this case.
  5. Research PureTech Health shares. The platform should provide the latest information available.
  6. Buy your PureTech Health shares. It's that simple.
The whole process can take as little as 15 minutes.

How has Coronavirus impacted PureTech Health's share price?

Since the stock market crash in March caused by coronavirus, PureTech Health's share price has had significant negative movement.

Its last market close was 250p, which is 23.31% down on its pre-crash value of 326p and 25.94% up on the lowest point reached during the March crash when the shares fell as low as 198.5p.

If you had bought £1,000 worth of PureTech Health shares at the start of February 2020, those shares would have been worth £701.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £877.20.

PureTech Health share price

Use our graph to track the performance of PRTC stocks over time.

PureTech Health shares at a glance

Information last updated 2020-12-18.
Open361p
High370p
Low353p
Close361.5p
Previous close363p
Change -1.5p
Change % -0.413%
Volume 459,979
Information last updated 2020-12-27.
52-week range198.5p - 382p
50-day moving average 305.3235p
200-day moving average 276.3134p
Wall St. target price3.55p
PE ratio 2.3518
Dividend yield N/A (0%)
Earnings per share (TTM) 158.6p
Promoted
eToro Free Stocks

Invest in PureTech Health shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy PureTech Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

PureTech Health price performance over time

Historical closes compared with the last close of 361.5p

1 week (2021-01-08) -10.30%
1 month (2020-12-17) -0.41%
3 months (2020-10-16) 44.60%
6 months (2020-07-17) 29.11%
1 year (2020-01-17) 22.96%
2 years (2019-01-17) 110.17%
3 years (2018-01-17) 108.96%
5 years (2016-01-15) 125.94%

Is PureTech Health under- or over-valued?

Valuing PureTech Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PureTech Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

PureTech Health's P/E ratio

PureTech Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, PureTech Health shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

PureTech Health financials

Revenue TTM £12.3 million
Gross profit TTM £-76,041,000
Return on assets TTM -8.55%
Return on equity TTM 94.12%
Profit margin 3845.36%
Book value 2.745p
Market capitalisation £1.1 billion

TTM: trailing 12 months

PureTech Health share dividends

We're not expecting PureTech Health to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

PureTech Health share price volatility

Over the last 12 months, PureTech Health's shares have ranged in value from as little as 198.5p up to 382p. A popular way to gauge a stock's volatility is its "beta".

PRTC.LSE volatility(beta: 0.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while PureTech Health's is 0.6253. This would suggest that PureTech Health's shares are less volatile than average (for this exchange).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

PureTech Health overview

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

  • How to buy Lemonade shares | $50.05

    Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Unity Software shares | $111.51

    Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor

  • How to buy FuelCell Energy shares | $3.745

    Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.

  • How to buy CloudCommerce shares | $0.1275

    Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor

  • How to buy Zomedica Pharmaceuticals shares | $0.93

    Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.

  • How to buy YRC Worldwide shares | $4.66

    Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.

  • How to buy Xeros Technology Group shares | 220p

    Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.

  • How to buy Xpediator shares | 33.5p

    Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.

  • How to buy Van Elle Holdings shares | 42p

    Ever wondered how to buy shares in Van Elle Holdings? We explain how and compare a range of providers that can give you access to many brands, including Van Elle Holdings.

  • How to buy ULS Technology shares | 80.7p

    Ever wondered how to buy shares in ULS Technology? We explain how and compare a range of providers that can give you access to many brands, including ULS Technology.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site